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We report  that activators and inhibitors of protein ki- 
nase C (PKC) and protein phosphatases regulate the ac- 
tivity of a cloned rat brain y-aminobutyric acid (GABA) 
transporter (GAT1) expressed in Xenopus oocytes. Four 
compounds  known to activate PKC increased GABA up- 
take 23.5-fold over basal control levels. Inhibition of 
PKC by bisindolylmaleimide reduced basal GABA up- 
take 80% and blocked the phorbol 12-myristate 13-ac- 
etate (Pa)-induced stimulation of transport. Okadaic 
acid, a protein phosphatase inhibitor, stimulated trans- 
port 2.5-fold; a 4-fold increase in GABA uptake occurred 
when  oocytes  were treated with cyclosporin A, a specific 
inhibitor of protein phosphatase 23. Modulation re- 
sulted in changes to v,, but not to K,,, and was influ- 
enced by the functional expression level of the  trans- 
porter protein; as expression level increased, the ability 
to up-regulate transporter activity decreased. Down- 
regulation of transporter activity was independent of 
expression level. Modulation did not occur through 
phosphorylation of the  three consensus PKC sites pre- 
dicted by the primary protein sequence since their re- 
moval had no  effect  on the susceptibility of the  trans- 
porter  to modulation by PMA or bisindolylmaleimide. 
Subcellular fractionation of oocyte  membranes  demon- 
strated  that  under basal level conditions, the majority of 
GATl  was targeted to a cytoplasmic compartment cor- 
responding to the trans-Golgi or Iow density vesicles. 
Stimulation of PKC with PMA resulted in a transloca- 
tion of transporters from this compartment to the 
plasma  membrane. At higher expression levels of  GATl 
protein, a larger portion of GATl was found on the 
plasma membrane during basal level conditions and 
treatment with bisindolylmaleimide resulted in removal 
of these transporters from the plasma  membrane. At ex- 
pression levels demonstrated to be resistant to modula- 
tion by  PMA, PMA-treatment still resulted in transloca- 
tion of transporters from the cytoplasm to the plasma 
membrane.  Thus, the inability of PMA to increase up- 
take at high expression of the GATl protein is due to 
saturation at a step subsequent to translocation. These 
findings 1) demonstrate the presence of a novel regu- 
lated secretory pathway in oocytes and 2) suggest a 
modulatory  mechanism for neurotransmitter  transport- 
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ers  that could have significant effects upon synaptic 
function. 
Transporters are integral membrane proteins that use a 
chemical or electrochemical gradient  to move molecules across 
membranes.  The  Na+-dependent  neurotransmitter  transport- 
ers  have  been localized to  the  presynaptic  terminals of neurons 
and  surrounding glia, suggesting  that one of their  functions is 
to  remove neurotransmitter from the  synaptic cleft. This  action 
could contribute to the  termination of synaptic  transmission 
(Iversen, 1975); however, electrophysiological analysis shows 
these  transporters  to  have slow kinetic  properties that  could 
substantially  limit  heir  ability  to  shape  synaptic  events 
(Sarantis et al., 1993; Mager et al., 1993). This  implies  that, if 
neurotransmitter  transporters  are  to affect the  time course of 
synaptic  transmission,  they  need to  be present at high  density 
at the  synapse or increase  their  turnover  rate.  Either  require- 
ment  suggests that modulation of transport could be  critical to 
transporter function  since regulatory  mechanisms  have  been 
shown to affect both of these processes. For example,  modula- 
tion of activity occurs for the  facilitated glucose transporter  via 
insulin-stimulated  translocation of the  protein from intracellu- 
lar stores  to  the  plasma  membrane  (Cushman  and Wardzala, 
1980; Suzuki and Kono, 1980). Alternatively, modulation of 
function occurs for other  membrane  proteins (e.g., ion chan- 
nels)  via  alterations of various  unitary  properties of the  protein 
(Kaczmarek, 1988; Sardet et al . ,  1990). Identification of the 
genes encoding neurotransmitter  transporters  has hown them 
to possess putative phosphorylation sites (for review see Amara 
and  Kuhar (1993))  which renders  them  candidates for modula- 
tory  mechanisms that could affect their activity. 
There is some evidence for protein  kinase-dependent modu- 
lation of endogenous neurotransmitter  transporters.  Using pri- 
mary  cultures from rat brain cortex, Casado et al. (1991) re- 
ported that phorbol esters produced a 50% increase  in 
glutamate transport in glial cells while having no effect on 
glutamate transport in neurons. Additionally, Gomeza et al. 
(1991) showed that PKC’ activation reduced GABA transport  in 
glial cells, with  no effect on neuronal GABA uptake.  In  both of 
these  reports,  the  failure of phorbol esters  to affect GABA and 
glutamate  transport in neurons  was not attributed  to a lack of 
PKC or to a non-functional PKC. Rather,  the  dissimilar effects 
of phorbol esters on neuronal  and  glial  transport were postu- 
butyric acid; OAG, l-oleoyl-2-acetyl-sn-glycerol; PMA, phorbol 12-my- 
The  abbreviations used are: PKC,  protein  kinase C; GABA, y-amino- 
ristate 13-acetate:  4aPDD,  4u-phorbol  12,13-didecanoate;  SC-10, 
N-heptyl-5-chloro-l-naphthalenesulfonamide; RER, rough endoplasmic 
reticulum. 
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14760 Modulation of Cloned GABA nansporter 
lated  to be due  to different  isotypes of PKC present in the two 
cell types (with varying sensitivity to phorbol esters), or to a 
smaller pool of PKC available in these neurons (Mudd and 
Raizada, 1990). Thus, it remains  to be determined  whether  the 
lack of protein kinase-dependent modulation is a general  fea- 
ture of neuronal  transporters,  whether  these  transporters  have 
the  potential  to be regulated via second messenger pathways 
and  the mechanisms underlying  such modulation. 
We have begun to address  these questions by examining the 
ability of a cloned rat brain  neuronal GABA transporter (GAT1) 
t o  be modulated by protein kinases and phosphatases. The 
GATl clone (Guastella et al., 1990) is representative of many of 
the recently cloned genes encoding neurotransmitter  transport- 
ers  in  that  its  primary protein  sequence shares significant ho- 
mology with other members of this  transporter subfamily and 
predicts a number of consensus phosphorylation sites (see 
Amara and Kuhar (1993)). In  this  report, we show that  the 
activity of the GATl clone expressed in Xenopus oocytes is 
regulated by PKC and protein phosphatases  and  demonstrate 
that  the observed modulation is  mediated by a regulated sub- 
cellular  redistribution of the  transporter. 
EXPERIMENTAL PROCEDURES 
Material~-[~H]GABA  was  purchased  from  DuPont  NEN. Bisindolyl- 
maleimide, OAG, PMA, 4aPDD,  and SC-10 were  purchased  from  Cal- 
biochem (San Diego, CA). Okadaic acid and cyclosporin A  were gifts of 
Dr. Joseph  Farley  (Indiana  University, Bloomington). Horseradish  per- 
oxidase-conjugated  donkey  anti-rabbit  Ig was  purchased  from  Amer- 
sham Corp. All other  reagents  were  obtained from Sigma. Cyclosporin 
A, okadaic acid, PMA, and  4aPDD  were dissolved at  high  concentration 
in 100% ethanol; bisindolylmaleimide, (-)-indolactam V, OAG, and 
SC-10 were dissolved a t  high  concentration in 100% Me,SO.  All drugs 
were then  serially  diluted  in ND96 (96 mM NaCl,  2 mM KCl, 1.8 mM 
CaCl,, 1 mM MgCI,, 5 mM Hepes,  pH 7.4) at  least 100-fold prior  to oocyte 
injection. 
Antisera-The polyclonal rabbit  antisera  3425  was  generated  against 
a peptide  corresponding  to the carboxyl terminus  (amino  acids 588-599) 
of the rat brain GABA transporter  GATl  (Guastella  et  al., 1990). 
Synthesis of mRNA and Mutagenesis of GATl-The  DNA template 
encoding GATI, which  was  used for in uitro transcription,  was  gener- 
ated by polymerase  chain  reaction from: 1) linearized  GATl in pBlue- 
script;  2) a sense  primer  consisting of the T7  promoter,  6  bases of the 
alfalfa mosaic virus  5"untranslated  leader  sequence  (Kain et al., 19911, 
an optimum  translation  initiation  sequence (Kozak, 1987), and  the first 
18 nucleotides of the GATl coding sequence; and 3) an  antisense  primer 
consisting of (5' to 3') a T,, sequence  and  the  terminal 18 bases of the 
GATl coding sequence.  Mutations of the  three  putatively  intracellular 
PKC phosphorylation  sites  were  performed  using  the  Clontech  Trans- 
former  Site-Directed  Mutagenesis Kit (Palo Alto, CA). Single  bases at 
each of the  three  sites, Se?,, Thr46,  and  Ser562,  were  mutated  to  create 
codons encoding Ala. The  mutations  were verified by sequencing 
through  the  appropriate  regions.  cRNAencoding  both  the wild-type and 
mutant  transporters  was  generated  using  the Ambion Megascript in 
vitro  Transcription Kit (Austin, TX). 
Xenopus Oocyte Expression and P'HIGABA Uptake Assays-These 
methods are described in detail elsewhere (Quick and Lester, 1994). 
Briefly, oocytes were  defolliculated and  maintained at 18 "C in ND96, 
supplemented  with  2.5 mM sodium pyruvate, 50 pg/ml  gentamycin,  and 
5% horse  serum (Quick et al., 1992).  Either 1 or 5 ng of GATl cRNA was 
injected  into  each oocyte and L3H1GABA uptake  assays  were  performed 
2-5 days  post-injection.  Unless  otherwise  noted,  all  modulation  experi- 
ments  were  performed on GATl oocytes expressing  basal GABA uptake 
levels of less  than  10 fmol [3H1GABA/oocyte/min.  Vehicle solutions  and 
drugs  were  administered by microinjection in 25-11] volumes. To meas- 
ure GABA uptake, oocytes were  incubated  in ND96 containing 260 nM 
[3HJGABA, after  which  the oocyte was  washed  three  times  in ND96, 
solubilized in 10% SDS,  and  quantified by liquid  scintillation  counting. 
Unless  otherwise  noted,  values  in  the  text  are  expressed  as  the  mean 
* S.D. 
Effect of Microinjection on GABA Uptake in  GATl-expressing 
Oocytes-To standardize  the  drug delivery procedure, all compounds 
were  introduced  into the oocyte by microinjection. Two control  experi- 
ments  were  performed  to verify that  there were no changes  in  uptake 
due  to  the microinjection technique: 1) 25 nl of ND96 medium were 
injected  to  examine the effect of microinjection on GABA uptake,  and  2) 
ethanol  and MeSO, (other vehicles used for drug solubilization)  were 
compared to ND96-injected oocytes. The  results of these  two  experi- 
ments showed no effect of ND96,  ethanol,  or MeSO, control  injections  on 
GABA uptake  (data  not  shown).  The  approximate  final  concentrations 
of ethanol  and MeSO, inside  the oocyte, assuming  an oocyte volume of 
0.5 pl, were  2  and 0.2%, respectively;  these  concentrations  were at least 
Mold  higher  than  the  concentrations  used for drug solubilization in  the 
experiments  described below. 
We find that microinjection provides a reliable  method for drug  ad- 
ministration  and provides several  advantages over incubation  methods. 
First,  injection of the  drug  into  the oocyte eliminates  the  requirement 
for diffusion across  the oocyte membrane,  thus  shortening  the  preincu- 
bation period. This allows the focus to  be  on effects which are  primarily 
post-transcriptionaUpost-translational. Microinjection into  the cyto- 
plasm also reduces the possibility that the compound or solvent is 
affecting the transporter indirectly by diffusion into the membrane 
bilayer. Ethanol, MeSO,, and  fatty  acids  can  intercalate  into  the  mem- 
brane  and  alter  membrane  fluidity  (Swann,  1984;  Klausner  et  al.,  1980) 
and  such  action  has,  in  turn,  been  shown to affect the C1- transporter  in 
corneal  epithelium  (Schaeffer  and  Zadunaisky, 1979), and  the Na+,K+- 
ATPase in bovine brain microsomes (Swann, 1984). 
Fractionation of Membranes-Total membrane  protein  was  isolated 
from uninjected and GAT1-expressing oocytes by homogenization in 
0.32 M sucrose  in  TE  buffer (50 mM Tris-C1, pH 7 .5 , l  mM EDTA, 200 
phenylmethlysulfonyl fluoride, 10 pg/ml aprotinin,  and 10 pg/ml leu- 
peptin) with 15 strokes of a tight-fitting pestle in a chilled Dounce 
homogenizer. The  homogenate  was  centrifuged twice at 1000 x g and 
membranes  were  pelleted a t  40,000 rpm  in a Beckman SW 41 rotor for 
30  min at 4 "C. The  pellets  were  resuspended in 50 mM Tris-C1, pH 7.5, 
1 mM EDTA, and  the  protein  content  was  determined by Bio-Rad Pro- 
tein  Assay (Richmond, CA). The  fractionation protocol used  was  a modi- 
fication from Corey and  Stallcup  (1992). Oocytes expressing  GATl  were 
injected  with  either PMA (final  concentration  400 nM) or bisindolylma- 
leimide  (final  concentration 100 nM) (150 oocytes were  injected  within 
20  min)  and  were  incubated  for an  additional 10 min  prior  to homog- 
enization.  Groups of 150 oocytes each  were homogenized in 2 ml of 0.32 
M sucrose and centrifuged as described above. The  final  supernatant 
was  immediately  layered on a discontinuous  sucrose  gradient of 2.0 M (2 
ml),  1.3 M (3.2 ml), 1.0 M (3.2 ml), and 0.6 M (2.0  ml)  sucrose  in  TE  buffer 
containing 5 mM MgC1,. After  centrifugation at 40,000 rpm  in a Beck- 
man SW 41 rotor  for  4 h a t  4 "C, 1-ml fractions  were collected from the 
bottom of the  gradient,  diluted 4-fold with 0.15 M sucrose  in TE buffer, 
and  the microsomal membranes  in  each  fraction  were  pelleted a  48,000 
rpm in a Beckman SW 50.1 rotor for 3 h at  4°C.  The pellets were 
resuspended  in  either  80 pl of 50 mM Tris-C1, pH 7.5, 1 lll~ EDTA (for 
membrane  marker  assays) or 15 pl of sample  buffer  (Laemmli,  1970) 
(for gel  electrophoresis). All samples  were  stored at -80 "C. 
Marker  Enzyme  Assays for Rough  Endoplasmic  Reticulum,  Plasma 
Membrane, and  Dans-Golgi-The  rough  endoplasmic  reticulum  mem- 
brane  marker, glucose 6-phosphatase,  was  assayed  according  to Corey 
and Stallcup (1992). Identification of plasma membranes and Golgi 
membranes  were  by  assays of Na,K-ATPase and  galactosyltransferase 
activity, respectively, and  were  performed by the methods of Hensley  et 
aE. (1989). 
Electrophoretic and Immunoblotting Analysis-Microsomal mem- 
brane  fractions  stored a t  -80 "C were  thawed at room temperature.  Pro- 
teins  were  separated on 10% SDS-polyacrylamide  gels  (Laemmli,  1970), 
transferred  to  nitrocellulose  membranes  (Schleicher & Scheull) for 4  h 
at 50 V, and  then blocked overnight a t  4 "C in  PBS  containing 0.1% 
Tween-20,5% skim  milk,  and 1% donkey  serum.  Antibodies  were  diluted 
and  the  membranes  were  washed  in  phosphate-buffered  saline  contain- 
ing 0.1% Tween-20 and 5% skim  milk.  The  immunoblotting  procedure 
consisted of the following steps  at room temperature:  incubation for 60 
min  with  the polyclonal antibody  against  GATl  (3425)  diluted 1:200, 
three  10-min  washes,  incubation for 30 min  with  horseradish peroxi- 
dase-conjugated donkey anti-rabbit Ig antibody diluted 1:1000, three 
IO-min washes, followed by detection  using ECL reagents  (Amersham 
Corp.).  The  antibody recognized a  67-kDa  band  in oocytes expressing 
GATl that  was  not  present  in uninjected oocytes (Fig. 1 )  and  the size is 
in  agreement  with  the  size of the product from an  in uitro translation of 
GAT-1 in  the absence of microsomal membranes  (Guastella  et  al., 1990). 
This is consistent  with  the conclusion that GAT-1 synthesized  in oocytes 
does not  contain  N-linked  sugars  and  was confirmed by lack of digestion 
of the 67-kDa band by endoglycosidase F/N-glycanase (Boehringer 
Mannheim) (data not shown). Quantification of band densities was 
done on the LKB Ultrascan  laser  densitometer. 
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FIG. 1. Immunoblot analysis of GATl expressed inXenopus oo- 
cytes. Membranes (60 pg of proteidane) prepared from uninjected 
oocytes (lane 1 )  and oocytes expressing  GATl (lane 2 )  were  subjected  to 
10% SDS-polyacrylamide gel electrophoresis and  transferred  to  a  nitro- 
cellulose filter. The filter was incubated with rabbit antisera raised 
against  synthesized  peptide  corresponding  to  the  COOH-terminal do- 
main of GATl  (amino  acids 588-599). Secondary  antibody  conjugated  to 
horseradish  peroxidase  was  incubated  with  the  filters,  and  the  bands 
were  visualized by enhanced  chemiluminescence. 
RESULTS 
GABA Uptake in GATl-expressing Oocytes Is  Modulated by 
Activation and Inhibition of PKC-Four different PKC activa- 
tors were found to  increase GABA transport (Fig. 2). In GAT1- 
expressing oocytes injected with  0.1 p~ (final  concentration) of 
the phorbol ester PMA, GABA transport  was  increased  to 206 2 
14% of basal  values.  This  stimulation of  GABA transport 1) did 
not occur following injection of 0.4 p~ of the  inactive phorbol 
ester  4aPDD (83 14% of basal  values)  and  2)  was  not  due to 
drug-induced changes  in  protein  synthesis, since co-injection of 
60 pg/ml cycloheximide, which resulted  in  greater  than 80% 
inhibition of protein  synthesis  as  determined by trichloroacetic 
acid precipitation, did not  inhibit  the PMA-induced stimulation 
(data  not shown). In  addition  to PMA, three  other  activators of 
PKC were  found to  increase GABA transport over  control  val- 
ues: 0.5 p~ OAG (Gilmore and  Martin, 1983),  208 * 10%; 0.3 p~ 
SC-10 (Nishino et al., 19861, 272 2 19%; and 2.5 p~ (-)-indo- 
lactam V (Sugimura, 19821,352 2 22%. In  support of the role of 
PKC in  modulating GABA transport activity, injection of 0.1 p~ 
bisindolylmaleimide, an inhibitor of PKC (Toullec et  al., 19911, 
reduced basal GABA uptake to 30 2 13% of control values. 
Additionally, GAT1-expressing oocytes were injected with ei- 
ther  0.1 PM bisindolylmaleimide or 0.4 p~ PMA alone, or in 
combination (Table I).  The 2-fold stimulation of  GABA trans- 
port produced by PMA was completely blocked by co-injection of 
bisindolylmaleimide. 
Inhibition of Protein  Phosphatases  Increases GABA 
Dunsport-The finding  that PKC activators  stimulated GABA 
transport suggested that  maintenance of proteins  in a phos- 
phorylated state  might be responsible for increasing  transport. 
Therefore, we tested  whether  inhibition of cellular phospha- 
tases would also  result  in  an  increase  in GABA transport (Fig. 
3). Injection of 100 nM okadaic acid (open circles) had no effect 
on uptake  in GAT1-expressing oocytes. However, transport  was 
increased to 154 14% and 260 * 5% of basal values with 
injection of 1 and  10 p ~ ,  respectively. Injection of 25 nM cyclos- 
porin A, an inhibitor of PP2B (calcineurin) (Friedman and 
Weissman, 19911, increased GABA uptake to 121% (closed 
circles), and  maximal 5-fold increases were  observed with 400 
nM. Furthermore, we injected GAT1-expressing oocytes with 
either cyclosporin A or PMA, or both. Transport  was  increased 
approximately 2-fold when  each  drug at 100 nM was injected 
alone; combined injection stimulated  transport  almost 3-fold 
over control values  suggesting  the ffects are  partially  additive 
(Table I). 
Modulatory Effects of PMA and Bisindolylmaleimide Are 
Concentration- and Time-dependent-PMA had no effect on 
GABA transport  at  10 nM while 50 nM increased  transport  to 
400 
300 
e, 
3 
3 
; 200 
; 
€8 
100 
0 1 I 
aPDD PMA OAG SCIO IndoV Bis 
FIG. 2. Effects of PKC activation and inhibition on rSH]GABA 
uptake. Oocytes were  injected  with 1 ng of  GAT-1  cRNA and  assayed 
for ['HIGABA uptake  2-4  days post-injection. All drugs  were  injected 
into  the oocyte in 25-111 volumes  to the following final  concentrations: 
CYPDD (0.4 PM), PMA(O.1 p~), OAG (0.5 PM), SC-10 (0.3 PM), indolactam 
V (2.5 PM), and  bisindolylmaleimide (0.1 PM). The  assay  time  was  15  min 
and was performed 30 min after microinjection of drugs. [?H]GABA 
uptake  data for the drug-injected oocytes are  listed  as a  percentage of 
the  uptake  in vehicle-only injected oocytes. Each  value  represents  the 
mean * S.D. for four  or five oocyteskondition; data shown for individual 
drugs  were  taken from a  single  batch of oocytes tested on the  same day. 
TABLE I
GABA  uptake  in  GATl-expressing oocytes 
Drug control uptake Percent of 
~ ~ ~ _ _ _ _ _  
PMA 
W mean ? S.D. 
0.4 212 f 15 
Bisindolylmaleimide 0.1 
PMA + bisindolylmaleimide 
23 2 21 
0.4 + 0.1 22 * 10 
PMA 0.1 212 * 10 
Cyclosporin A 0.1 226 14 
PMA + cyclosporin A 0.1 + 0.1 284 r 12 
approximately 130% of control values (Fig. 4, open circles). 
Maximal increases were achieved with injections of 100 nM. 
Injection of 1 nM bisindolylmaleimide decreased GABA uptake 
approximately 20%, and  maximal  inhibition of 75% occurred 
with 50 nM (Fig. 4, closed circles). 
The  time course of  GABA uptake  stimulation by PMA (400 
nM), okadaic  acid  (10 p~), or cyclosporin A (1.0 p~), and inhibi- 
tion by bisindolylmaleimide  (100 nM), is shown in Fig. 5 .  Oka- 
daic acid (open squares) and cyclosporin A (closed squares) 
showed maximal  stimulation of transport (approximately 280 
and 200%, respectively) 30 min after injection, and this in- 
crease  remained  stable for the  duration of the 50-min assay. 
PMA (circles)  produced peak  stimulation (approximately 225% 
of control) after 40 min, followed  by a slight decline thereafter. 
Bisindolylmaleimide (triangles)  inhibited  uptake by  40% 
within 15 min,  and  maximal  inhibition of 80% was observed by 
35 min. 
Kinetic Analyses of GABA Dansport  during Modulation- 
The  mechanism  underlying  the observed modulation was ex- 
amined by kinetic  analyses of  GABA transport  in  the presence 
or absence of bisindolylmaleimide or PMA. Analysis of an 
Eadie-Hofstee  plot  for ND96-injected GAT1-expressing oocytes 
determined a K,  of 4.1 p~ and a V,, of 58.4 fmol/min (Fig. 6A). 
Treatment of a parallel group of oocytes with bisindolylmalei- 
mide had  little effect on K, (5.2 PM) but decreased V,, by 56% 
(25.6 fmol/min). In a separate  experiment  examining  the effects 
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FIG. 3. Effects of okadaic acid and cyclosporin A on [SH]GABA 
uptake. Oocytes  were injected with 1 ng of GAT-1 cRNA and assayed 
for r3H1GABA uptake 2-3 days post-injection. Okadaic acid  (open 
circles) or  cyclosporin A (closed circles) was injected into the oocyte in 
25-nl  volumes  to final concentrations as shown. c3H1GABA uptake was 
assayed 30 min after microinjection. L3HIGABA uptake data for the 
drug-injected oocytes are listed as a percentage of the  uptake  in vehicle- 
only injected oocytes. Each value represents the mean * S.D. for  four or 
five oocytes/condition. The data are representative of three experi- 
ments. 
250 
200 
T p - $ 4  
0.1 1 10 100 1000 
Concentration (nM) 
FIG. 4. Concentration curves for PMA and bisindolylmalei- 
mide. Oocytes  were injected with 1 ng of  GAT-1  cRNA and assayed for 
C3HlGABA uptake 2-3 days post-injection. PMA (open circles) or bisin- 
dolylmaleimide (closed circles) was injected into the oocyte in 25-111 
volumes to final concentrations as shown. PHIGABA uptake was as- 
sayed 30 min after microinjection. I3H1GABA uptake data for the drug- 
injected oocytes are listed as a percentage of the  uptake in vehicle-only 
injected oocytes. Each value represents the mean * S.D. for  four or five 
oocytes/condition. The data  are representative of three experiments. 
of PMA, the K,,, and V, values  determined for control oocytes 
were 5.8 1” and 1.1 fmol/min, respectively  (Fig. 6B).  Treatment 
of oocytes with PMA had no effect on K, (5.3 PM) but  increased 
V,, by almost 200% (2.1 fmol/min). These  results  indicate  that 
the PMA- and bisindolylmaleimide-induced effects on GABA 
transporter  activity  are  primarily  due  to  changes  in  the maxi- 
mum velocity of transport,  with only minimal  changes  to  the 
apparent  ligand affinity. 
Effect of GATl Expression Level on Modulation of PHIGABA 
400 1 
300 - 
200 ~ 
100 - - 
10 20 30 40 50 
Total Drug Exposure Time (min) 
[’HIGAEiA uptake subsequent to drug application in GAT-1 in- 
FIG. 5. The time course of increases and decreases in 
jected oocytes. Oocytes were injected with 1 ng GAT-I cRNA and 
assayed for L3H1GABA uptake 2-3 days post-injection. All drugs were 
injected into the oocyte in 25-nl  volumes to the following final concen- 
trations: 0.1 PM bisindolylmaleimide (triangles), 1 p~ cyclosporin A 
(squares), 0.4 p~ PMA (circles), and 10 p~ okadaic acid  (open squares). 
The total exposure time (abscissa) refers to the time following drug 
injection, including the assay time. Assay times ranged from 5-30 min. 
C3HlGABA uptake data for the drug-injected oocytes are plotted on the 
ordinate as a percentage of the uptake  in vehicle-only injected oocytes. 
Each data point represents the mean * S.D. for four or five oocytes/ 
condition; data shown  for individual curves were taken from within the 
same batch of oocytes tested on the same day. The S.D. for the vehicle- 
injected control  oocytes ranged from *9 to 219%. 
Uptake-Throughout the  concentration  and  time course  experi- 
ments,  it  was noted that  the expression level of the  transporter 
protein had a significant effect on the modulation of GABA 
uptake. We examined  this effect more closely through  post hoc 
analyses of our PMA and bisindolylmaleimide data as a  func- 
tion of various GATl expression levels. The  results of these 
analyses  are  shown  in Fig. 7. Since there is currently no suit- 
able ligand for measuring B,, the expression level of the 
transporter  was  quantified by measuring GABA uptake (fem- 
tomoles of [3H]GABA/oocyte/min) in vehicle-injected (control) 
oocytes expressing GAT1. Injections of 400 nM PMA (filled 
circles) produced a 1.5-3.2-fold increase over control transport 
at expression  levels of 5 fmol of [3H]GABA/oocyte/min or  less. 
This up-regulation of activity decreased as expression level 
increased. At expression  levels greater  than  approximately 13 
fmol of [3H]GABA/oocyte/min, PMA had  little effect on trans- 
porter  activity compared to control oocytes. Across this  same 
range of expression, there  was no effect of expression level on 
transporter activity inhibition by bisindolylmaleimide (open 
circles). 
This effect was more readily observed within  the  same  batch 
of oocytes in which varying expression  levels were achieved by 
performing uptake  assays at different  times  after GATl injec- 
tion. The effect of PMA (Fig. 7, connected circles) was  highest at 
an expression level of approximately 2 fmol/oocyte/min (220%) 
and decreased (to 150%) as expression increased  to 4 fmol of 
[3H]GABA/oocyte/min. At an expression level of 14 fmol of 
[3H]GABA/oocyte/min, PMA increased  transporter  activity by 
only 20% and  the effect was no longer  observed when expres- 
sion reached  16 fmol/oocyte/min. The  concentration of 
L3H1GABA was  in at least 10-fold excess; therefore,  the  absence 
of stimulation of transporter  activity  at  high GATl  expression 
levels was  not  due  to a limiting  amount of substrate. 
Effect of Removal of Putative  PKC  Sites on Modulation of 
GATl by PMA and Bisindolylmaleimide-To determine if 
modulation was occurring via direct phosphorylation of the 
putative PKC sites on GAT1, we generated a mutant  trans- 
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FIG. 6. Saturation curves and Eadie-Hofstee transformations for control, bisindolylmaleimide-, and PMA-treated oocytes. 
L3H1GABA accumulation was measured for GABA concentrations from 0.5 PM to 20 PM. Oocytes were either  untreated (basal), injected with 100 
n~ bisindolylmaleimide (A) or injected with 400 n~ PMA ( B )  20 min prior to the 15 min assay. Eadie-Hofstee plots  were obtained with the  data 
sets from the saturation curves. V, GABA uptake (femtomoles/oocyte/min); and S, free substrate concentration. The average standard  error of the 
mean for both experiments was 14.6%. Experiments shown are representative of four separate experiments. 
porter  in which all three of the  intracellular consensus PKC 
sites  were  eliminated. Removal of the consensus PKC sites did 
not affect the modulation of the  transporter by either PMA or 
bisindolylmaleimide compared to  the wild-type GABA trans- 
porter (Fig. 8). Similar  results were obtained from three experi- 
ments across three different batches of oocytes. In  each experi- 
ment,  the expression level of the wild-type and  mutant  proteins 
were  approximately equal  (data not shown). I t  is possible that 
modulation could result from direct phosphorylation of non- 
consensus PKC sites; however, we chose to  investigate  other 
potential  mechanisms for modulation. 
Effects of PMA and Bisindolylmaleimide on Oocyte Mem- 
brane Potential-The transporter encoded by GATl is electro- 
genic (Kavanaugh et al., 1992; Mager et al., 1993) and  thus  the 
driving force for GABA transport is dependent upon the  resting 
membrane  potential of the oocyte. Therefore, one hypothesis is 
that  the observed  modulation is due  to drug-induced  changes in 
membrane potential. To test this, we used a standard two- 
electrode voltage-clamp configuration (Quick and Lester,  1994) 
and  made  measurements of oocyte membrane  potentials 5 min 
prior to microinjection and  then continuously 5-40 min post- 
injection. The oocytes were injected with ND96, ethanol, 
MeSO,, PMA, or bisindolylmaleimide (three to  five oocytes/ 
condition; three-oocyte batches). Pre-injection membrane po- 
tentials of all oocytes measured were  between -35 and -50 mV. 
In 70% of the oocytes tested, a slight change from the  base line 
resting  potential (<8 mV) to  less negative potentials  was ob- 
served, but only within  the  first  10  min post-injection. These 
changes  appeared  to be related  to  the microinjection procedure 
and were not specific to  any of the injected  modulatory drugs. 
Therefore, PMA and bisindolylmaleimide are  not  modulating 
GABA transport by exerting an  effect on membrane  potential. 
Effects of PMA and Bisindolylmaleimide on GATl Subcellu- 
lar Localization-The PKC-mediated  changes in V,,,, the de- 
pendence of modulation on expression  level, and  the inability to 
eliminate  the observed modulation by removal of the consensus 
PKC sites suggested to  us  that  the effect could be due  to move- 
ment of transporters  to  and from the  plasma membrane. This 
type of modulation has been well characterized for the facili- 
tated glucose transporters: insulin-activated glucose uptake 
into  fat cells is  due  to  translocation of transporters from intra- 
cellular vesicles to  the  plasma  membrane  (Cushman  and 
Wardzala, 1980; Suzuki  and Kono, 1980). To determine if GATl 
is modulated by a similar mechanism it  was necessary to  iden- 
tify the  intracellular  compartment(s)  in which GATl  resides. 
This was done by subcellular fractionation of the oocyte to 
separate  the  membranes of the rough  endoplasmic reticulum 
(RER), plasma  membrane,  and trans-Golgi.  Membrane  prepa- 
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Decem
ber 27, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
14764 Modulation of Cloned GABA Dansporter 
350 
300 i 
I 
0 
0 
0 5 10 15  20
Expression Level (fmol/oocyre/min) 
FIG. 7. Effect of GAT-1 expression level on modulation of 
['HIGABA uptake by PMA and bisindolylmaleimide in oocytes. 
Oocytes  were  injected  with 1 or 5 ng of GAT-1 cRNA and assayed for 
r3HIGABA uptake 2-5 days post-injection.  The  assay  time was 15 min. 
Prior  to  assay, the oocytes were  injected  with 25 nl of a vehicle  solution, 
or a solution containing PMA (0.4 PM, 15-25 min before assay) or bisin- 
was quantified as the amount of PHIGABA uptake in the vehicle-in- 
dolylmaleimide (100 nM, 0-10 min before assay). The  expression  level 
jected oocytes and is plotted on the abscissa. The percent change in 
uptake compared to the vehicle-injected oocytes is plotted on the ordi- 
nate for PMA-injected (closed symbols) and bisindolylmaleimide-in- 
jected (open symbols)  oocytes.  Each data point represents the mean f 
S.E. for three to Eve oocytes. Data points  connected  by the solid line 
represent an experiment  performed on the same batch of injected oo- 
cytes; different  expression  levels  for this batch were achieved by per- 
forming the assay at varying  times after cRNA injection.  The standard 
error of the means  for the vehicle-injected oocytes varied  from *2 to  
+24% (mean = f10.7%). 
400 r 
300 
GATl wild-type GATl mutant 
FIG. 8. Effect of removal of PKC sites on modulation of GATl 
activity by PMA and bisindolylmaleimide. Single  bases at each of 
the three PKC consensus sites, Seg4, Tl -~r~~,  and Sef16*, were mutated to 
create codons encoding  Ala.  The mutations were verified by sequencing 
through these regions. cRNA encoding  both the wild-type and mutant 
transporters was generated  and 1 ng was injected  into oocytes which 
were assayed 2-3 days  post-injection. Either PMA or bisindolylmalei- 
mide was microinjected to a final concentration of 400 and 100 m, 
respectively. The oocytes were assayed for L3H1GABA uptake 15 min 
after drug injection; the assay time was 30 min.  [3HlGABA uptake data 
for the drug-injected oocytes are plotted on the ordinate as a percentage 
of the uptake in  vehicIe-only  injected  oocytes.  Each data point  repre- 
sents the mean  S.D. for four or five oocyteskondition; data shown  for 
individual  curves  were taken from within the same  batch of oocytes 
tested on the same  day. 
rations from uninjected oocytes that were untreated (basal 
level), PMA-injected, or bisindolylmaleimide-injected were 
fractionated on a discontinuous  sucrose  gradient.  Fractions col- 
lected  from the gradient  were  assayed for specific enzymes  and 
a typical gradient profile is  presented  in Fig. 9. As expected, 
each  marker  enzyme  was  enriched at the  appropriate  gradient 
interface: glucose 6-phosphatase  (identifying RER membranes) 
at the lowest gradient  interface corresponding to  fractions 2 
and 3, Na+/K+  ATPase (plasma  membrane) at the middle inter- 
face or in fraction 5, and  galactosyltransferase (trans-Golgi) at 
the  upper  interface (fractions 9 and 10). Distribution of the 
marker enzymes, and  thus  the corresponding membranes,  were 
unaffected by PMA and bisindolylmaleimide treatment  (Fig. 9). 
To determine if PMA was  inducing a translocation of cyto- 
plasmic transporters to  the  plasma  membrane, we performed 
subcellular  fractionation of basal  and  PMA-treated oocytes and 
a representative  experiment is shown in Fig. 10. In the  basal 
untreated  state  all of the  detectable GATl protein  was found in 
a subcellular compartment corresponding to the trans-Golgi 
network (Fig. lOA, fractions 8-10). This indicates that the 
transporter  is  primarily  targeted  to a cytoplasmic compartment 
for storage  rather  than  expressed  constitutively on the  plasma 
membrane. After PMA treatment,  the population of transport- 
ers previously  found in the Golgi fractions  was  present on the 
plasma  membrane (Fig. lOB, fraction 5) ,  leaving no detectable 
transporter in the Golgi fractions (Fig. lOB, fractions 9 and 10). 
A band of approximately 80 kDa is also observed in  several of 
the  fractions  and  was  determined  to be nonspecific due  to  its 
presence in uninjected oocytes (data not shown). [3H]GABA 
uptake  assays  using oocytes taken  prior  to h mogenization con- 
firmed  that PMA treatment  increased  transport  activity as ex- 
pected and  indicated  the presence of functional  transporters on 
the  plasma  membrane below the level of detection by immuno- 
blot analyses. 
We next  investigated  whether  the reduction in  uptake activ- 
ity  seen  with bisindolylmaleimide was  due  to removal of trans- 
porters from the cell surface. Oocytes were  either  untreated or 
microinjected with bisindolylmaleimide  (100 nM final concen- 
tration) 30 min prior to homogenization. Since the effect of 
bisindolylmaleimide  on transport  activity  was found to be in- 
dependent of expression level (see Fig. 7 above), we expressed 
GATl at higher levels (confirmed by uptake  assays performed 
in parallel)  to  ensure  detectability of the  transporter on the 
plasma membrane in the basal state. The amount of trans- 
porter in each fraction was quantified by densitometry and 
calculated as a percentage of total transporter in all of the 
fractions. Localization of transporter during the basal state 
(Fig. 1L4) demonstrated  approximately 16% of total  transport- 
ers located in fraction 5, corresponding to  plasma  membrane; 
the  remaining 84% were found in  fractions 9 and 10, corre- 
sponding to Golgi-associated membranes. We think  it likely 
that  the  increased  detectability of transporter  associated  with 
the  plasma  membrane  fractions  was  not only due  to  an  increase 
in overall transporter  synthesis at the  higher  expression level 
(as determined by prior  uptake  analyses)  but  also  due  to  an 
"overflow" of transporter from a regulated  pathway  to a  consti- 
tutive pathway, as discussed in  further  detail below. In oocytes 
that had been treated with bisindolylmaleimide (Fig. 11B), 
there  were no detectable  transporters  in  fraction 5, indicating 
that the  remaining  transporters associated with the plasma 
membrane  were below detectability by immunoblot. 
The  data from the  uptake  experiments  demonstrated  that 
high expression  levels of GATl protein  eliminates  the ability of 
PMA to  modulate  transport activity. The  data from the subcel- 
lular  fractionation  experiments  demonstrated that PMA treat- 
ment results in translocation of transporters from the cyto- 
plasm  to  the  plasma  membrane.  These  observations  raise  the 
question of whether  the  inability of PMA to  modulate  transport 
activity at higher expression  levels is related  to  the  transloca- 
tion of transporters or another mechanism. To address this 
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FIG. 9. Sucrose  gradient  profiles for marker  enzymes  identify- 
ing RER, plasma membrane, and trans-Golgi. Membranes  were 
prepared from uninjected oocytes that were untreated (basal level), 
PMA-injected (0.4 PM), and bisindolylmaleimide-injected (0.1 p~), and 
analyzed by equilibrium  sedimentation on discontinuous  sucrose gra- 
dients,  as  described  under  “Experimental  Procedures.”  Marker  enzymes 
were  assayed as described, and  the  enzyme  activity  in  each  fraction  was 
plotted as a percentage of the  total  enzyme  activity  found  in  all  frac- 
tions.  This is a representative  example from four  separate  experiments. 
A B E R M  m 
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FIG. 10. The effect of PMA on the  subcellular  distribution of 
the GATl protein. Membranes  were  prepared from GAT1-expressing 
oocytes that were  either  untreated  (basal  level) (A)or PMA-injected (0.4 
PM) (B) .  They  were  analyzed by equilibrium  sedimentation on discon- 
tinuous sucrose gradients as  described under “Experimental Proce- 
dures.’’ The  membrane  pellets  were  resuspended  and  subjected  to  SDS- 
polyacrylamide  electrophoresis,  transferred  to  nitrocellulose,  and  GATl 
protein was visualized by immunoblotting. This is a representative 
example from four  separate  experiments. TGN, trans-Golgi  network. 
question, we performed subcellular localization analyses of the 
GATl  protein in oocytes expressing high  levels of transporter 
during  the  basal  state  and lso after PMA treatment (Fig. 12A). 
By uptake assay, we determined  that  the expression level was 
high  enough that  transporter activity was  not  altered by  PMA 
treatment  (data  not shown). During  the  basal  state, 45% of 
total  transporters were found associated with  the  plasma mem- 
A m m  E N  
1 2 3 4 5 6 7 8 9 1 0  
~ 
67 kd - c- 0- 
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67 kd - “ 
1 1  12 
FIG. 11. The effect of bisindolylmaleimide  on  the  subcellular 
distribution of GATl. Membranes  were  prepared from GAT1-express- 
ing oocytes that were  either  untreated  (basal  level) (A) or bisindolyl- 
maleimide-injected (0.1 PM) (B) .  They were analyzed by equilibrium 
sedimentation on discontinuous  sucrose  gradients as described under 
“Experimental  Procedures.”  The  membrane  pellets  were  resuspended 
and subjected to SDS-polyacrylamide electrophoresis, transferred to 
nitrocellulose, and GATl protein was visualized by immunoblotting. 
This  is a representative  example from four  separate  experiments. TGN, 
trans-Golgi  network. 
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FIG. 12. The effect of high  expression levels of GATl protein  on 
PMA-induced  translocation of the transporter. Membranes  were 
prepared from oocytes expressing  uptake  levels of 34 fmol/min/oocyte 
that were  untreated  (basal  level) (A) or PMA-injected (B) .  They were 
analyzed by equilibrium  sedimentation on discontinuous  sucrose  gra- 
dients,  as  described  under  “Experimental  Procedures.”  The  membrane 
pellets were resuspended, subjected to SDS-polyacrylamide electro- 
phoresis,  and  transferred to nitrocellulose,  and GATl protein  was visu- 
alized by immunoblotting.  TGN,  trans-Golgi  network. 
branes (fraction 5) and 55% were located in fraction 9, corre- 
sponding to low density vesicles. After treatment  with PMA, 
88% of the  transporters were found associated  with the plasma 
membranes (fraction 6) and 12% of the  transporters remained 
associated with  the Golgi fractions  (Fig.  12B). 
DISCUSSION 
It is  thought  that one of the major  functions of neurotrans- 
mitter  transporters  is  the  termination of synaptic  transmission 
by uptake of transmitter from the  synaptic cleft into  surround- 
ing  neurons  and glia. Therefore, the  stimulation  or inhibition of 
transport via  second-messenger pathways could play  a signifi- 
cant role in  synaptic function. Molecular cloning and charac- 
terization of the  neurotransmitter  transporters reveal putative 
consensus phosphorylation sites (Amara and Kuhar, 19931, 
lending  support  to  the possibility of transporter modulation. In 
primary astrocyte cultures, phorbol esters affect glutamate  and 
GABA uptake differentially, increasing glutamate transport 
while decreasing GABA transport. Modulation of a cloned neu- 
rotransmitter  transporter expressed heterologously would pro- 
vide an  opportunity  to  further  these observations and examine 
potential mechanisms underlying these effects. Through the 
use of direct cytoplasmic microinjection of second-messenger 
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14766 Modulation of Cloned GABA Dansporter 
activators  and  inhibitors we have  demonstrated  the modula- 
tion of a GABA transporter expressed in Xenopus oocytes and 
describe the mechanism underlying  this modulation. 
Activation of PKC by both phorbol esters (PMA and OAG) 
and  other  agents (SC-10 and (-)-indolactam V) increased GABA 
transport. PMA-induced stimulation could be blocked by bisin- 
dolylmaleimide, suggesting  that PKC was  responsible for the 
increase in transport. The increase in transport elicited by 
PMA was not due  to  an  increase  in  transport protein synthesis 
since the effect was observable in  the presence of cyclohexi- 
mide. In addition, the increase in transport was seen after 
acute  treatment with PMA, lending  support  to a post-transla- 
tional effect on the transporter. The phosphatase inhibitors 
okadaic acid and cyclosporin A  also increased GABA transport, 
implying that  the  maintenance of proteins  in a phosphorylated 
state is involved in modulation. However, removal of the con- 
sensus PKC sites found in  the  primary amino acid sequence of 
GATl had no effect on the  regulation of transporter activity, 
suggesting  that phosphorylation could be occurring a t  non-con- 
sensus  sites on the  transporter or the PKC effect on transporter 
activity  was via an  indirect mechanism. 
An indirect modulatory  mechanism is observed for the facili- 
tated glucose transporters  in  that  insulin rapidly activates glu- 
cose transport in fat cells, primarily by translocating the 
GLUTl  and GLUT4 isoforms from subcellular compartments 
to the  plasma  membrane (Wardzala et al., 1978; Blok et al., 
1988; Calderhead et al., 1990). Therefore, we chose to  test  the 
hypothesis that PKC was modulating  uptake activity by redis- 
tribution of the GABA transporter from a cytoplasmic location 
to  the  plasma membrane.  Subcellular localization of the  trans- 
porter in the basal state and after PMA treatment demon- 
strated  that modulation  was consistent  with changes in mem- 
brane trafficking. In  the  basal  state,  the majority of 
transporters were found in a compartment corresponding to  the 
trans-Golgi, or low density vesicles, with little  or no detectable 
transporter on the  plasma membrane. After PMA treatment, 
transporters were no longer found in  the trans-Golgi  compart- 
ment  but only on the  plasma  membrane,  indicating  that PKC 
activation resulted  in  transporter translocation. Other  data we 
obtained are  consistent  with  this f nding. 1) The  time course we 
observed for the PMA-induced increase  in  transporter  activity 
is comparable to the  time course for the  translocation kinetics 
of the facilitated glucose transporter (Yang et al., 19921, and 2) 
the  kinetic  data  demonstrate  that modulation affected primar- 
ily V, rather  than K,, suggesting  changes  in  the  number of 
transporters on the cell surface  resulting from increased exo- 
cytosis. It  is also possible that  the observed changes in V,,, are 
due to changes in transporter turnover rate rather than 
changes  in  the  number of surface transporters;  it is difficult to 
quantify  the  actual  number of surface carriers because there is 
currently no suitable ligand for determining a true B,,,. In 
addition,  the modulation  may not be completely due  to  trans- 
location of transporters but may also involve conversion of 
transporter between  active and inactive states.  This possibility 
is supported by the evidence indicating  that at high expression 
levels of the  transporter, PMA still  stimulates  the  translocation 
of transporter from the cytoplasm to  the  plasma  membrane  yet 
there is no measurable  increase  in  transport activity. 
Inhibition of PKC with bisindolylmaleimide resulted in a 
decrease in transporter activity during the basal state and 
blocked transporter  stimulation by PMA. This  latter effect is 
most  probably due  to  the inhibition of the PKC-induced trans- 
location of transporters  to  the  plasma embrane. However, the 
reduction of transporter activity from basal levels requires  ad- 
ditional interpretation.  The decrease in V,, after bisindolyl- 
maleimide treatment is consistent with removal of transporter 
from the cell surface and  this is confirmed by the subcellular 
localization of the  transporter  during  the  basal  state  and  after 
PKC inhibition. This  suggests a low level of transporter  that is 
continuously on or recycled to  the  plasma  membrane  and  that 
this  is mediated by basal PKC activity. Further activation of 
PKC may alter  this  relationship,  resulting  in  an increase in 
transporters moving to  the  plasma  membrane and/or remain- 
ing on the cell surface.  Another possibility is that down-regu- 
lation of transporter activity by bisindolylmaleimide is due  to a 
selective degradation of surface transporters. However, we 
think  this hypothesis is unlikely  since there is still a reservoir 
of cytoplasmic transporters  that  can be recruited  to  the  plasma 
membrane by the  same mechanism that places transporters on 
the cell surface during  the  basal  state. Therefore,  inhibition of 
PKC is most likely affecting a translocation process rather  than 
a degradative one. 
Two basic types of exocytotic pathways  exists  in eukaryotic 
cells: 1) a constitutive pathway  in which macromolecules are 
transported  to  the cell surface as soon as  they  are synthesized 
and  2) a regulated  pathway  in which macromolecules are  tar- 
geted for storage in cytoplasmic vesicles until a triggering 
event  stimulates exocytosis. We found that  the GABA trans- 
porter expressed in Xenopus oocytes is targeted  to a regulated 
pathway for storage  until PKC activation triggers translocation 
of transporters  to  the  plasma  membrane. As transporter pro- 
tein levels increased so did the  amount of transporter found on 
the  plasma  membrane  during  the  basal  state.  This  finding  is 
consistent  with evidence that overexpression of heterologously 
expressed proteins  results  in normally regulated  proteins being 
expressed constitutively, as if “overflowing“ to the  alternate 
pathway.2 
An important question resulting from our  study is how GATl 
is targeted  to a cytoplasmic storage location under  basal con- 
ditions. Of the facilitated glucose transporters endogenously 
expressed in adipocytes and muscle cells, GLUTl  is expressed 
constitutively on the  plasma  membrane while GLUT4 is tar- 
geted  to cytoplasmic vesicles (Harrison et al., 1990). This ob- 
servation  extends  to expression of these two isoforms in  mam- 
malian cell lines  (Shibasaki et al., 19921, thus allowing Asano et 
al. (1992) to construct chimeras between the two isoforms in 
order to  identify  potential targeting signals. Their  results sug- 
gest  that two domains govern targeting of GLUT4 to cytoplas- 
mic vesicles, of which one domain  encompasses a leucine  hep- 
tad repeat. A leucine zipper motif is also found in GATl 
(Guastella et al., 1990) and appears to be conserved among 
other members of the neurotransmitter transporter family 
(Amara  and  Kuhar, 1993); however, no function has been at- 
tributed  to  this region. 
GATl expression level influenced the ability of  PMA to 
stimulate  transport activity; however, overexpression of trans- 
porter protein does not appear to saturate the “machinery” 
necessary for translocation. Rather  it affects a step  subsequent 
to  translocation, possibly vesicle fusion with  the  plasma mem- 
brane. I t  is unclear why this effect occurs since the  transporter 
can be expressed at even higher levels than at that which we 
found no increase  in  activity upon PMA treatment.  This is an  
important question that  remains  to be resolved and which will 
potentially be elucidated when the  steps involved in  the ob- 
served  modulation are described in  further  detail. 
The  steps involved in  the movement of secretory vesicles has 
been well studied (for review see Kelly (199311, and  the  entire 
neurotransmitter secretory  mechanism has been reconstituted 
in  several  systems, including Xenopus oocytes (Alder and Poo, 
1993). For example,  Ca2+-dependent  secretion of glutamate  has 
been demonstrated in oocytes injected with total rat brain 
mRNA (Alder et al., 1992). Furthermore,  Scheuner et a2. (1992) 
demonstrated that the constituents of chromaffin secretory 
S. Pfeffer,  personal  communication. 
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vesicle membranes are sufficient to reconstitute exocytosis 
when injected into Xenopus  oocytes and propose that  the inter- 
changeability of mammalian and amphibian secretory pathway 
components suggests substantial biochemical conservation of 
the regulated exocytotic pathway. Our data reveal a novel regu- 
lated secretory pathway present  in Xenopus  oocytes that  has 
the ability to recognize a rat neuronal GABA transporter. 
Therefore, the Xenopus  oocyte is not only a convenient system 
for examining the potential for proteins to  be modulated, it may 
provide a useful model for studying the modulatory mecha- 
nisms present in other cell systems. 
The finding that a  neurotransmitter  transporter is modu- 
lated by a mechanism similar to the modulation of a facilitated 
glucose transporter is significant since there is no primary 
amino acid identity between members of the two transporter 
families. This would suggest a common “signal” in  the second- 
ary  structures of these  transporters which  may  confer this par- 
ticular mode of modulation. It  is also significant that modula- 
tion by membrane trafficking first identified for the facilitated 
glucose transporter expressed endogenously in adipocytes and 
muscle cells is also found to modulate a GABA transporter 
expressed exogenously in Xenopus oocytes. It remains to be 
determined whether modulation by this mechanism is found 
for  endogenously expressed neurotransmitter  transporters; 
however, the presence of a sophisticated exocytotic pathway 
has been well established in neurons (for review see Kelly 
(1993)). This particular mode of modulation would have impor- 
tant implications for the proposed functions of neurotransmit- 
ter transporters. For example, GABA uptake inhibitors in- 
crease and prolong GABA, transmission (Solis and Nicoll, 
1992); therefore, increasing the number of GABA transporters 
near GABA, receptors would further  shape  the time course of 
these synaptic events. Our data provide  evidence that  the den- 
sity of GABA transporters at the plasma membrane has  the 
potential to be regulated by a mechanism involving a second 
messenger cascade. 
We demonstrate PKC-regulated modulation of a cloned neu- 
ronal GABA transporter expressed inXenopus oocytes and  that 
modulation is mediated primarily through subcellular redistri- 
bution of transporters to and from cytoplasmic storage com- 
partments and the plasma membrane. Thus, expression in Xe- 
nopus  oocytes and microinjection of modulatory compounds  will 
provide a convenient system in which to study the regulation of 
additional neurotransmitter  transporters  as well as elucidate 
the mechanisms involved in protein targeting  and regulated 
exocytosis. 
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